title: Will sialylation change intravenous immunoglobulin therapy in the future?
authors.affiliation: CSL Behring, Research and Development, Bern, Switzerland.
authors.forename: F
authors.initials: F
authors.lastname: Käsermann
authors.forename: I K
authors.initials: IK
authors.lastname: Campbell
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000276:immunology / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D007141:Immunoglobulin Fc Fragments / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000627:therapeutic use*; D051379:Mice
chemical_list: D000893:Anti-Inflammatory Agents; D007140:Immunoglobulin Fab Fragments; D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous